It has been hypothesized that fetal prematurity or Intrauterine Growth Restriction (IUGR) could be related to the presence of factor V of Leiden mutation. This mutation is associated with a higher incidence of pregnancy difficulties that can result in preterm birth. The frequency of Leiden mutation was investigated in the group of newborns with a low birth weight below 1500 g over a six-year period from 2015 to 2020. During this period, 339 newborns were tested, of which 42 newborns with V Leiden mutation (12.4%) were detected. The average of its occurrence frequency in the Czech population was determined as 5.0% based on published studies. In our research, the occurrence of the V Leiden mutation was found significantly higher in newborns under 1500 g. At the same time, we did not demonstrate an increased frequency of births at lower gestational weeks, lower birth weight, or an association with sex in newborns with a positive diagnosis of the Leiden V factor.

Department of Genetics Hospital Ceske Budejovice Bozeny Nemcove 54 37001 Ceske Budejovice Czech Republic

Department of Mathematics College of Polytechnics Tolsteho 16 58601 Jihlava Czech Republic

Department of Technical Studies College of Polytechnics Tolsteho 16 58601 Jihlava Czech Republic

Faculty of Health and Social Sciences University of South Bohemia J Boreckeho 1167 37011 Ceske Budejovice Czech Republic

Institute of Experimental Medicine AS CR Videnska 1083 14220 Prague Czech Republic

Laboratory of Molecular Biology and Genetics Hospital Ceske Budejovice Bozeny Nemcove 54 37001 Ceske Budejovice Czech Republic

Neonatology Department Hospital Ceske Budejovice Bozeny Nemcove 54 37001 Ceske Budejovice Czech Republic

Zobrazit více v PubMed

Dahlbäck B., Carlsson M., Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA. 1993;90:1004–1008. doi: 10.1073/pnas.90.3.1004. PubMed DOI PMC

Van Cott E.M., Khor B., Zehnder J.L. Factor V Leiden. Am. J. Hematol. 2016;91:46–49. doi: 10.1002/ajh.24222. PubMed DOI

Kujovich J., Adam M., Ardinger H., Pagon R. GeneReviews. University of Washington; Seattle, WA, USA: 2006. PubMed

Riedlova P., Kramna D., Ostrizkova S., Tomaskova H., Jirik V. Examination of in Factor V Leiden and Prothrombin II Thrombophilic Mutations in Czech Young Women Using ddPCR-Prevalence and Cost-Benefit Analysis. Healthcare. 2021;9:1656. doi: 10.3390/healthcare9121656. PubMed DOI PMC

Kvasnička J. Dědičné trombofílie—doporučení k provádění genetických testů v klinické praxi. Časopis Lékařů Českých. 2010;149:424–427. PubMed

Kvasnicka J., Hájková J., Bobcíková P., Kvasnicka T., Dusková D., Poletínová S., Kieferová V. Prevalence of thrombophilic mutations of FV Leiden, prothrombin G20210A and PAl-1 4G/5G and their combinations in a group of 1450 healthy middle-aged individuals in the Prague and Central Bohemian regions (results of FRET real-time PCR assay) Časopis Lékařů Českých. 2012;151:76–82. PubMed

Kvasnička T. The Association of atherothrombosis and thrombophilias—Genetic aspects. Vnitr Lek. 2014;60:880–884. PubMed

Paseka J., Unzeitig V., Horejsi J., Rotta L., Chroust K., Cibula D. Clinical study of a triphasic contraceptive preparation (Norgestimate 180/215/250 micrograms + ethinylestradiol 35 micrograms) in a population of Czech women. Ceska Gynekol. 1999;64:246–254. PubMed

Albagoush S.A., Koya S., Chakraborty R.K., Schmidt A.E. Factor V Leiden Mutation. StatPearls Publishing; Treasure Island, FL, USA: 2022. PubMed

Khialani D., Le Cessie S., Lijfering W.M., Cannegieter S.C., Rosendaal F.R., Vlieg A.V.H. The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. Br. J. Haematol. 2020;191:90–97. doi: 10.1111/bjh.16666. PubMed DOI PMC

Martinelli I., De Stefano V., Taioli E., Paciaroni K., Rossi E., Mannucci P.M. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb. Haemost. 2002;87:791–795. PubMed

van Vlijmen E.F., Wiewel-Verschueren S., Monster T.B., Meijer K. Combined oral contraceptives, thrombophilia and the risk of venous thromboembolism: A systematic review and meta-analysis. J. Thromb. Haemost. 2016;14:1393–1403. doi: 10.1111/jth.13349. PubMed DOI

Battinelli E.M., Marshall A., Connors J.M. The Role of Thrombophilia in Pregnancy. Thrombosis. 2013;2013:1–9. doi: 10.1155/2013/516420. PubMed DOI PMC

Abdel Ghaffar T.Y., Elsayed S.M., Sakr M.A., Elsobky E.S., Abdelhakam S.M., Yousuf S., Egin Y., Akar N. Factor V G1691A (Leiden) is a major etiological factor in Egyptian Budd-Chiari syndrome patients. Turk. J. Haematol. 2011;28:299–305. doi: 10.5152/tjh.2011.84. PubMed DOI

Deltenre P., Denninger M.-H., Hillaire S., Guillin M.-C., Casadevall N., Brière J., Erlinger S., Valla D.-C. Factor V Leiden related Budd-Chiari syndrome. Gut. 2001;48:264–268. doi: 10.1136/gut.48.2.264. PubMed DOI PMC

Campello E., Spiezia L., Radu C.M., Bon M., Gavasso S., Zerbinati P., Woodhams B., Tormene D., Prandoni P., Simioni P. Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. Thromb. Haemost. 2012;108:633–639. doi: 10.1160/TH12-05-0280. PubMed DOI

Kujovich J.L. Thrombophilia and pregnancy complications. Am. J. Obstet. Gynecol. 2004;191:412–424. doi: 10.1016/j.ajog.2004.03.001. PubMed DOI